Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2018 1
2019 2
2020 1
2021 4
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Medication guide for the perioperative management of oral antineoplastic agents in cancer patients.
Villanueva-Bueno C, Escudero-Vilaplana V, Collado-Borrell R, Giménez-Manzorro Á, Ribed A, Marzal-Alfaro B, Revuelta-Herrero JL, Gonzalez-Haba E, Herranz A, Sanjurjo M. Villanueva-Bueno C, et al. Among authors: marzal alfaro b. Expert Opin Drug Saf. 2022 Jan;21(1):107-119. doi: 10.1080/14740338.2021.1965990. Epub 2021 Aug 12. Expert Opin Drug Saf. 2022. PMID: 34357828 Review.
Aggressiveness of end-of-life cancer care: what happens in clinical practice?
García-Martín E, Escudero-Vilaplana V, Fox B, Collado-Borrell R, Marzal-Alfaro B, Sánchez-Isac M, Solano-Garzón ML, González Del Val R, Cano-González JM, Pérez de Lucas N, Bravo-Guillén AI, Valero-Salinas J, González-Haba E, Sanjurjo M, Martín M. García-Martín E, et al. Among authors: marzal alfaro b. Support Care Cancer. 2021 Jun;29(6):3121-3127. doi: 10.1007/s00520-020-05828-9. Epub 2020 Oct 16. Support Care Cancer. 2021. PMID: 33067765
Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents.
Escudero-Vilaplana V, Collado-Borrell R, Gómez Martínez-Sagrera P, Villanueva-Bueno C, Revuelta-Herrero JL, Gonzalez-Haba E, Hoyo-Muñoz Á, Jerez Gilarranz Y, Marzal-Alfaro B, Herranz A, Martin M, Sanjurjo M. Escudero-Vilaplana V, et al. Among authors: marzal alfaro b. J Cancer Res Clin Oncol. 2023 Jul;149(7):2855-2882. doi: 10.1007/s00432-022-04172-1. Epub 2022 Jul 6. J Cancer Res Clin Oncol. 2023. PMID: 35790560
Development and Evaluation of a Clinical Decision Support System to Improve Medication Safety.
Ibáñez-Garcia S, Rodriguez-Gonzalez C, Escudero-Vilaplana V, Martin-Barbero ML, Marzal-Alfaro B, De la Rosa-Triviño JL, Iglesias-Peinado I, Herranz-Alonso A, Sanjurjo Saez M. Ibáñez-Garcia S, et al. Among authors: marzal alfaro b. Appl Clin Inform. 2019 May;10(3):513-520. doi: 10.1055/s-0039-1693426. Epub 2019 Jul 17. Appl Clin Inform. 2019. PMID: 31315138 Free PMC article.
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Escudero-Vilaplana V, Collado-Borrell R, Del Monte-Millán M, Hoyo-Muñoz A, Gómez Martínez-Sagrera P, Revuelta-Herrero JL, Marzal-Alfaro B, Gonzalez-Haba E, López-Tarruella Cobo S, Jerez Gilarranz Y, Herranz A, Sanjurjo M, Martin M. Escudero-Vilaplana V, et al. Among authors: marzal alfaro b. Support Care Cancer. 2021 Aug;29(8):4673-4681. doi: 10.1007/s00520-021-06016-z. Epub 2021 Jan 28. Support Care Cancer. 2021. PMID: 33506273
Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice.
Escudero-Vilaplana V, Revuelta-Herrero JL, Collado-Borrell R, Marzal-Alfaro B, Gimenez-Manzorro A, Herranz-Alonso A, Sanjurjo-Saez M. Escudero-Vilaplana V, et al. Among authors: marzal alfaro b. Expert Opin Drug Saf. 2019 Sep;18(9):861-868. doi: 10.1080/14740338.2019.1641197. Epub 2019 Jul 15. Expert Opin Drug Saf. 2019. PMID: 31282227
Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App.
Escudero-Vilaplana V, Romero-Medrano L, Villanueva-Bueno C, Rodríguez de Diago M, Yánez-Montesdeoca A, Collado-Borrell R, Campaña-Montes JJ, Marzal-Alfaro B, Revuelta-Herrero JL, Calles A, Galera M, Álvarez R, Herranz A, Sanjurjo M, Artés-Rodríguez A. Escudero-Vilaplana V, et al. Among authors: marzal alfaro b. Front Oncol. 2022 Jul 13;12:880430. doi: 10.3389/fonc.2022.880430. eCollection 2022. Front Oncol. 2022. PMID: 35936756 Free PMC article.
DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach.
Villalvazo P, Marzal-Alfaro B, García-Alfonso P, Revuelta-Herrero JL, Thomas F, López-Tarruella S, García-González X, Calvo A, Yakoubi M, Salvador-Martín S, López-López F, Aguilar I, Sanjurjo-Sáez M, Martín M, López-Fernández LA. Villalvazo P, et al. Among authors: marzal alfaro b. J Pers Med. 2021 Aug 13;11(8):792. doi: 10.3390/jpm11080792. J Pers Med. 2021. PMID: 34442436 Free PMC article.
Level of concordance between two risk-assessment models for predicting venous thromboembolism in medical patients at admission.
De Lorenzo-Pinto A, García-Sánchez R, Durán-García E, Castuera-Gil A, Pascual-Izquierdo C, Marzal-Alfaro B, Arrabal-Durán P, Herranz-Alonso A, Andueza-Lillo JA, Sanjurjo-Sáez M. De Lorenzo-Pinto A, et al. Among authors: marzal alfaro b. Eur J Hosp Pharm. 2016 May;23(3):141-144. doi: 10.1136/ejhpharm-2015-000694. Epub 2015 Nov 6. Eur J Hosp Pharm. 2016. PMID: 31156835 Free PMC article.